10 Things For Pfizer's New CEO To Worry About
Executive Summary
Albert Bourla will face opportunities and potential pitfalls.
You may also be interested in...
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.